Greenwich LifeSciences

GLSINasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$214.595 M

$14.62 -10.58%

Close of 6 Nov 2026

As of 6 Nov 2026, Greenwich LifeSciences (GLSI) has a market capitalization of $214.6M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$19.4M

Loss-making

Shares outstanding

14,678,208

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →

#239ImmuneeringIMRX$217.9M
#240Vanda PharmaceuticalsVNDA$217.7M
#241Greenwich LifeSciencesGLSI$214.6M
#242Siga TechnologiesSIGA$213.0M
#243AC ImmuneACIU$212.7M

Insiders buying

All insider buying →

3 open-market purchases by officers and directors of Greenwich LifeSciences, worth $97.0K. Grants and option exercises are excluded.

Snehal PatelCEO and CFO$29.6K
2,200 shares at $13.43 on 28 Jul 2026 · filed 30 Jul 2026
Snehal PatelCEO and CFO$20.4K
1,500 shares at $13.62 on 27 Jul 2026 · filed 29 Jul 2026
Snehal PatelCEO and CFO$47.0K
3,600 shares at $13.06 on 23 Jul 2026 · filed 27 Jul 2026

What if Greenwich LifeSciences were worth as much as…

Open the what-if tool →

Gold $28.2T

$1,923,728

Per share 131,582× higher

Bitcoin $1.53T

$104,089.55

Per share 7,120× higher

Apple $5.02T

$341,716.28

Per share 23,373× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Greenwich LifeSciences are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.